The sensor system is different than existing transcutaneous sensors from Abbott and Dexcom, which use a small needle to measure glucose in the interstitial fluid under a patient’s skin and last as long as 15 days.
Instead of numerous applications of a CGM like those, the Eversense 365 sensor is fully implanted under a patient’s skin in a single procedure to provide a full year of glucose monitoring and integration with automated insulin delivery systems such as the Sequel Med Tech twiist pump.
“Once the user gets the product, they can use the system as they want to for up to a year,” Senseonics VP of Product Development Hari Sree said in a Medical Design & Outsourcing interview.
The implant sends continuous glucose sensing data to a transmitter device attached to the patient’s skin with a silicone adhesive. This transmitter then sends the data to a mobile app, where the patient can evaluate their glucose levels and take action.
“The sensor works by having communication with the transmitter every time it wants to take a reading of the interstitial fluid’s glucose,” said Sree.
Get the full story at our sister site, Medical Design & Outsourcing.
